Hemispherx Biopharma (HEB)

Must be logged in to add this company to your watchlist.

Click here to login.

HEB - AMEX - 3/11/2010 8:00 PM

0.83
Change 0.07
% Change 9.21%
Market Cap Revenue Growth Profit Margin Cash
$104.78M 100% -12150% $61.04M
3539 / 4696 127 / 4687 4682 / 4693 1995 / 4139

For the September 2009 quarter, Hemispherx Biopharma spent an unknown percentage of gross profits on R&D and an unknown percentage on SGA expenses. Revenues rose 100% year-over-year to $0.02M. The company is trading at an unknown amount times earnings(PE) and 654.87 times revenue(PSR). At the end of September 2009, Hemispherx Biopharma had $61.04M in cash on hand and $0 in long-term debt. On 11/09/2009, Hemispherx Biopharma reported net loss of $2.43M, with diluted earnings per share of $-0.02.

Valuation

Add More Charts

Price

Current stock price.

PE Ratio

Price paid for a share relative to the annual income earned.

Price to Sales Ratio: 654.87

Market cap divided by revenue.

Growth & Profitability

Add More Charts

Revenue Growth: 100%

Revenue growth year-over-year.

Earnings per Share: $-0.02

Portion of profit allocated to each outstanding share of common stock.

Profit Margin: -12150%

Margin made on every dollar of revenue.

Fundamentals

Add More Charts

Income Statement

Summary of revenues, expenses & profits.

Balance Sheet

Company's assets, liabilities & shareholders' equity at a specific point in time.

Cash Flow

Cash inflows arise from one of three activities - operations, financing, or investing.